The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
CLINICAL COUNTERPOINT: Vitamin D: New Actions, New Analogs, New Therapeutic Potential*
Abstract
AN EXCITING new era has developed in the vitamin D field with the discovery of new target tissues, mechanisms of action, and selective analogs. As a clinical counterpoint article, this review will emphasize the potential clinical applications of these new discoveries. Many of the applications to be discussed remain untested, whereas others remain in their infancy. A major reason for optimism in predicting an expanding list of therapeutic applications for the vitamin D metabolites and analogs stems from the development of analogs of calcitriol that differ in their biological effects. In particular, analogs are now available that appear to separate the effects of calcitriol on growth and differentiation from effects on intestinal calcium absorption or bone mobilization. This apparent selectivity may reflect altered pharmacokinetic properties or may involve mechanistic differences at the cellular level as well. Regardless, the development of these drugs is likely to lead to clinical applications in which raising serum calcium need not accompany other actions. The initial portion of this review is devoted to a discussion of these analogs. The main goal of this article is to review those areas in which calcitriol and its analogs are being used in new ways and to describe potential applications that are suggested by the newly discovered actions of calcitriol. Thus, new concepts in vitamin D action have led to clinical trials of calcitriol and its analogs in the management of hyperparathyroidism and psoriasis, and trials of these drugs in certain malignancies or immunological disorders may not be far off. None of the clinical applications discussed are approved applications for these drugs. Rather, this review is intended to link the laboratory observations of the past decade with the bedside of the next decade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
Cited by
Lips, P. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.4.0437 · Cited by 2,118
Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice
Bouillon, R., Carmeliet, G., Verlinden, L., van Etten, E., Verstuyf, A., Luderer, H. F., Lieben, L., Mathieu, C., & Demay, M. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0004 · Cited by 1,783
Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)
Ahonen, M. H., Tenkanen, L., Teppo, L., Hakama, M., & Tuohimaa, P. (2000) · Cancer Causes & Control · doi:10.1023/a:1008923802001 · Cited by 494
Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3
Mathieu, C., Waer, M., Laureys, J., Rutgeerts, O., & Bouillon, R. (1994) · Diabetologia · doi:10.1007/bf00403372 · Cited by 434
The Vitamin D Receptor and the Syndrome of Hereditary 1,25-Dihydroxyvitamin D-Resistant Rickets*
Malloy, P. J., Pike, J. W., & Feldman, D. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.2.0359 · Cited by 395
Metadata
- Authors
- BIKLE, D. D.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 1992-11
- Volume
- 13
- Issue
- 4
- Pages
- 765-784
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2045870793
- Cited by
- 230
- References
- 1
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CLINICAL COUNTERPOINT: Vitamin D: New Actions, New Analogs, New Therapeutic Potential*. https://app.cochat.ai/papers/10.1210/edrv-13-4-765
- The paper
- BIKLE, D. D. (1992). CLINICAL COUNTERPOINT: Vitamin D: New Actions, New Analogs, New Therapeutic Potential*. Endocrine Reviews. https://doi.org/10.1210/edrv-13-4-765
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.